MarketInOut Stock Screener Log In | Sign Up
 

Crescent Biopharma Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Crescent Biopharma Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization480.49 mln
Float30.91 mln
Earnings Date11/05/2026

Piotroski F-Score

6 / 9
Solid

1-Year Forecast

31.50
Transformational upside

Relative Strength

19 / 100
Significantly lagging

Debt / Equity

0.01
Debt-free

Pre-Tax Margin

-1,373%
Severely loss-making

ROE

-102
Deeply negative

Business Description

Crescent Biopharma is a US-based cancer drug development company founded in 2024 and based in Waltham, Massachusetts. Its most advanced drug candidate, CR-001, is currently in Phase 3 clinical trials as a treatment for solid tumors, with two additional candidates, CR-002 and CR-003, also in development. The company works alongside Sichuan Kelun-Biotech to bring new cancer treatments to market.

Key Fundamentals

EPS-7.63
ROE-102
RPS0.43
ROIC-1,114
ROA-89.95
EBITDA, mln-163
EV / EBITDA-2.62
EV / EBIT-2.61
Revenue, mln11.88
EV / Revenue35.89

Quote Details

Last 12.82
Change -0.32 (-2.44%)
Open 13.36
Volume 390,184
Turnover 5,002,159
Average Volume 329,417

Financial Ratios

Pre-Tax Profit Margin-1,373
Leverage Ratio1.12
Current Ratio9.66
Price / Book2.55
Price / Tangible Book2.55
Debt / Equity0.01
Price / Sales25.60

Financial Strength

Altman Z-Score13.35
Piotroski F-Score 6 / 9
1-Year Target Price31.50
Short Ratio8.78
Short % of Float22.07

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 8.28% 93 / 100   
1 Month -9.97% 30 / 100   
2 Months -14.82% 26 / 100   
6 Months -48.31% 13 / 100   
1 Year 0.71% 49 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog